Adeno-associated virus (AAV) gene therapy for neurological disease
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Diseases of the central nervous system (CNS) have provided enormous opportunities for the therapeutic application of viral vector gene transfer. Adeno-associated virus (AAV) has been the vector of choice in recent clinical trials of neurological disease, including Parkinson’s and Alzheimer’s disease, due to the safety, efficacy, and stability of AAV gene transfer to the CNS. This review highlights the strategies employed for improving direct and peripheral targeting of therapeutic vectors to CNS tissue and considers the significance of cellular and tissue transduction specificity, transgene regulation, and other variables that influence achievement of successful therapeutic goals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456 · cited 2×
“The discovery that self-complementary (sc)AAV9 readily crosses the bloodebrain barrier to transduce brain and spinal neurons (Foust et al., 2008) has raised the possibility of gene therapy for non-focal neurological disorders.”
BackgroundAstrocytic Purinergic Signaling Coordinates Synaptic Networks
Pascual, O., Casper, K. B., Kubera, C., Zhang, J., Revilla-Sanchez, R., Sul, J.-Y., Takano, H., Moss, S. J., McCarthy, K., & Haydon, P. G. (2005) · Science · doi:10.1126/science.1116916 · Cited by 1,280 · cited 1×
“In vivo astrocytic adenosine kinase (ADK) activity limits extracellular adenosine levels by catabolizing adenosine into 50- AMP upon cellular uptake (Pascual et al., 2005; Zimmermann, 2000).”
BackgroundReversal of Neurological Defects in a Mouse Model of Rett Syndrome
Guy, J., Gan, J., Selfridge, J., Cobb, S., & Bird, A. (2007) · Science · doi:10.1126/science.1138389 · Cited by 1,230 · cited 2×
“For instance, in Rett syndrome, for which the transcriptional-regulation enzyme MeCP2 has reduced functionality, replacement of normal MeCP2 expression in young and even adult MeCP2-deficient mice led to recovery of largely normal physiological and behavioral phenotypes (Guy et al., 2007).”
BackgroundKaplitt, M. G., Feigin, A., Tang, C., Fitzsimons, H. L., Mattis, P., Lawlor, P. A., Bland, R. J., Young, D., Strybing, K., Eidelberg, D., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60982-9 · Cited by 1,067
Retrograde Viral Delivery of IGF-1 Prolongs Survival in a Mouse ALS Model
Kaspar, B. K., Lladó, J., Sherkat, N., Rothstein, J. D., & Gage, F. H. (2003) · Science · doi:10.1126/science.1086137 · Cited by 872 · cited 2×
“, 2010), and employment of retrograde transport has even been found to attenuate symptoms in a mouse model of amyotrophic lateral sclerosis (Kaspar, 2003).”
BackgroundBurger, C., Gorbatyuk, O. S., Velardo, M. J., Peden, C. S., Williams, P., Zolotukhin, S., Reier, P. J., Mandel, R. J., & Muzyczka, N. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.05.024 · Cited by 741
Davidson, B. L., Stein, C. S., Heth, J. A., Martins, I., Kotin, R. M., Derksen, T. A., Zabner, J., Ghodsi, A., & Chiorini, J. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3428 · Cited by 531 · cited 4×
“…that in rodent brain and spinal cord, most serotypes are considered ‘superior’ to AAV2with regard to total transduced brain volume and total number of transduced cells (Burger et al., 2004; Davidson et al., 2000; Paterna et al., 2004; Peng et al., 2011; Taymans et al., 2007; Weinberg et al., 2011).”
InfluentialGray, S. J., Matagne, V., Bachaboina, L., Yadav, S., Ojeda, S. R., & Samulski, R. J. (2011) · Molecular Therapy · doi:10.1038/mt.2011.72 · Cited by 501 · cited 3×
“…to i.v. AAV delivery include the low transduction ratio of neurons to glia in adult animals, including non-human primates (Gray et al., 2011), as well as the extent of non-CNS tissue unintentionally targeted using the peripheral administration strategy (Duque et al., 2009; Gray et al., 2011).”
BackgroundSelf-citationSelective induction of astrocytic gliosis generates deficits in neuronal inhibition
Ortinski, P. I., Dong, J., Mungenast, A., Yue, C., Takano, H., Watson, D. J., Haydon, P. G., & Coulter, D. A. (2010) · Nature Neuroscience · doi:10.1038/nn.2535 · Cited by 495 · cited 10×
“One exception to the i.c.v.-intracerebral relationship is AAV5, which, despite it’s efficacy at transducing neurons via intracerebral injection, shows limited neuronal transduction through i.c.v. delivery (Passini et al., 2003; Watson et al., 2005).”
BackgroundInfluentialSamulski, R. J., Berns, K. I., Tan, M., & Muzyczka, N. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.6.2077 · Cited by 466
Self-citationComparative Analysis of Adeno-Associated Viral Vector Serotypes 1, 2, 5, 7, And 8 in Mouse Brain
Taymans, J.-M., Vandenberghe, L. H., Haute, C. V. D., Thiry, I., Deroose, C. M., Mortelmans, L., Wilson, J. M., Debyser, Z., & Baekelandt, V. (2007) · Human Gene Therapy · doi:10.1089/hum.2006.178 · Cited by 305 · cited 2×
“…that in rodent brain and spinal cord, most serotypes are considered ‘superior’ to AAV2with regard to total transduced brain volume and total number of transduced cells (Burger et al., 2004; Davidson et al., 2000; Paterna et al., 2004; Peng et al., 2011; Taymans et al., 2007; Weinberg et al., 2011).”
BackgroundJanson, C., McPhee, S., Bilaniuk, L., Haselgrove, J., Testaiuti, M., Freese, A., Wang, D.-J., Shera, D., Hurh, P., Rupin, J., et al. (2002) · Human Gene Therapy · doi:10.1089/104303402760128612 · Cited by 255 · cited 3×
“For instance, the very first AAV clinical trial, one for Canavan’s disease, may have benefited by greater amounts of ASPA transgene expression from oligodendrocytes, which was prevented by the use of a neuron-specific promoter (Janson et al., 2002).”
BackgroundKlein, R. L., Dayton, R. D., Tatom, J. B., Henderson, K. M., & Henning, P. P. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300331 · Cited by 196 · cited 12×
“For instance, AAV8 or AAV5 with constitutive promoter-driven expression generally produce almost exclusive neuronal expression.”
BackgroundInfluentialGray, S. J., Blake, B. L., Criswell, H. E., Nicolson, S. C., Samulski, R. J., & McCown, T. J. (2010) · Molecular Therapy · doi:10.1038/mt.2009.292 · Cited by 185 · cited 1×
“A wholly different strategy entails the directed evolution of chimeric AAV capsids that target particular CNS cell populations, while potentially avoiding targeting to other tissues (Gray et al., 2010) (Fig.”
BackgroundSelf-citationLawlor, P. A., Bland, R. J., Mouravlev, A., Young, D., & During, M. J. (2009) · Molecular Therapy · doi:10.1038/mt.2009.170 · Cited by 161 · cited 2×
“Presently, two promoters have been successfully used to drive AAV-based transgene expression in specific cell types: myelin basic protein (MBP) promoter for oligodendrocyte expression, and glial fibrillary acidic protein (GFAP) promoter for astrocytes (Chen et al., 1999; Lawlor et al., 2009).”
BackgroundMethodHaberman, R. P., McCown, T. J., & Samulski, R. J. (2000) · Journal of Virology · doi:10.1128/jvi.74.18.8732-8739.2000 · Cited by 139 · cited 2×
“For example, when AAV2 was packaged with only the terminal repeats and a reporter GFP transgene, low-level expression of GFP was observed in vivo (Haberman et al., 2000) (Fig.”
BackgroundSelf-citationTowne, C., Schneider, B. L., Kieran, D., Redmond, D. E., & Aebischer, P. (2010) · Gene Therapy · doi:10.1038/gt.2009.119 · Cited by 124 · cited 1×
“Retrograde delivery of viral vectors from muscle to spinal motor and sensory neurons can bemoderately efficient depending on AAV pseudotype (Towne et al., 2010), and employment of retrograde transport has even been found to attenuate symptoms in a mouse model of amyotrophic lateral sclerosis…”
BackgroundHadaczek, P., Forsayeth, J., Mirek, H., Munson, K., Bringas, J., Pivirotto, P., L McBride, J., Davidson, B. L., & Bankiewicz, K. S. (2009) · Human Gene Therapy · doi:10.1089/hum.2008.151 · Cited by 90
Harding, T. C., Dickinson, P. J., Roberts, B. N., Yendluri, S., Gonzalez-Edick, M., Lecouteur, R. A., & Jooss, K. U. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.807 · Cited by 45 · cited 1×
“Generally, research has deemed AAV8 as more efficacious in transducing CNS tissue than AAV5, which itself has folds-greater efficacy of transduction throughout the CNS than AAV2 (Harding et al., 2006; Weinberg et al., 2011).”
BackgroundControlled dissemination of AAV vectors in the primate brain
Varenika, V., Kells, A. P., Valles, F., Hadaczek, P., Forsayeth, J., & Bankiewicz, K. S. (2009) · Progress in Brain Research · doi:10.1016/s0079-6123(09)17511-8 · Cited by 33 · cited 2×
“Such delivery improvements, along with in situ visualization of delivered materials (Varenika et al., 2009), can substantially improve targeting accuracy, increasing the likelihood of therapeutic success.”
Background
Cited by
The art of CHO cell engineering: A comprehensive retrospect and future perspectives
Fischer, S., Handrick, R., & Otte, K. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2015.10.015 · Cited by 312
Gene therapy for neurological disorders: progress and prospects
Deverman, B. E., Ravina, B. M., Bankiewicz, K. S., Paul, S. M., & Sah, D. W. Y. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.110 · Cited by 306
Felberbaum, R. S. (2015) · Biotechnology Journal · doi:10.1002/biot.201400438 · Cited by 264
Extracellular vesicles and intercellular communication within the nervous system
Zappulli, V., Friis, K. P., Fitzpatrick, Z., Maguire, C. A., & Breakefield, X. O. (2016) · Journal of Clinical Investigation · doi:10.1172/jci81134 · Cited by 255
Lymphatic drainage system of the brain: A novel target for intervention of neurological diseases
Sun, B.-L., Wang, L.-H., Yang, T., Sun, J.-Y., Mao, L.-L., Yang, M.-F., Yuan, H., Colvin, R. A., & Yang, X.-Y. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.08.007 · Cited by 255
Metadata
- Authors
- Weinberg, M. S., Samulski, R. J., & McCown, T. J.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2013-06
- Volume
- 69
- Pages
- 82-88
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W2093771404
- Cited by
- 154
- References
- 20
- FWCI
- 9.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.